190 related articles for article (PubMed ID: 21665249)
21. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
[TBL] [Abstract][Full Text] [Related]
23. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
24. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.
Fujimura M; Hidaka T; Kataoka K; Yamakawa Y; Akada S; Teranishi A; Saito S
Am J Surg Pathol; 2001 May; 25(5):667-72. PubMed ID: 11342781
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical expression of ERα, ERβ, and TFF1 in type I and II ovarian tumors.
Abdou AG; Aiad HA; Asaad NY; Abd El-Wahed MM; Serag El-Dien M
Appl Immunohistochem Mol Morphol; 2014 Jul; 22(6):421-32. PubMed ID: 24162262
[TBL] [Abstract][Full Text] [Related]
26. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
28. Cytoplasmic expression of oestrogen receptor beta (ERβ) as a prognostic factor in vulvar squamous cell carcinoma in elderly women.
Zannoni GF; Prisco MG; Vellone VG; De Stefano I; Vizzielli G; Tortorella L; Fagotti A; Scambia G; Gallo D
Histopathology; 2011 Nov; 59(5):909-17. PubMed ID: 22092402
[TBL] [Abstract][Full Text] [Related]
29. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
[TBL] [Abstract][Full Text] [Related]
31. [Influence of gonadotropin-releasing hormone agonist on the effects of chemotherapy upon ovarian cancer: an experimental study with rat model].
Yuan GW; Shen K; Yang JX
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1428-31. PubMed ID: 16029659
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
33. Immunostaining Study on the Expression of NF-κB, ER, and PR in Ovarian Serous Carcinoma.
Lin J; Xi C; Liu C; Wang Y; Liu Y; Ren C; Liu C
Int J Gynecol Pathol; 2017 Jan; 36(1):58-63. PubMed ID: 27171541
[TBL] [Abstract][Full Text] [Related]
34. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
Shaaban AM; Green AR; Karthik S; Alizadeh Y; Hughes TA; Harkins L; Ellis IO; Robertson JF; Paish EC; Saunders PT; Groome NP; Speirs V
Clin Cancer Res; 2008 Aug; 14(16):5228-35. PubMed ID: 18698041
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.
Geisler JP; Buller E; Manahan KJ
Eur J Gynaecol Oncol; 2008; 29(2):126-8. PubMed ID: 18459544
[TBL] [Abstract][Full Text] [Related]
36. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Létourneau IJ; Quinn MC; Wang LL; Portelance L; Caceres KY; Cyr L; Delvoye N; Meunier L; de Ladurantaye M; Shen Z; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
BMC Cancer; 2012 Aug; 12():379. PubMed ID: 22931248
[TBL] [Abstract][Full Text] [Related]
37. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer.
Ciucci A; Zannoni GF; Travaglia D; Scambia G; Gallo D
Hum Pathol; 2015 Aug; 46(8):1138-46. PubMed ID: 26003478
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival.
Halon A; Materna V; Drag-Zalesinska M; Nowak-Markwitz E; Gansukh T; Donizy P; Spaczynski M; Zabel M; Dietel M; Lage H; Surowiak P
Pathol Oncol Res; 2011 Sep; 17(3):511-8. PubMed ID: 21207255
[TBL] [Abstract][Full Text] [Related]
40. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
